+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
B

Actively Recruiting

Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.

Age: 0Years - 130YearsAll GendersPhase Not Applicable
39 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
R

Actively Recruiting

Researchers are evaluating the use of intravenous hyperoncotic albumin compared to normal saline boluses in critically ill patients suffering from Acute Kidney Injury requiring renal replacement therapy AKI-RRT. This trial aims to determine whether albumin administration during renal replacement therapy sessions increases organ support-free days and renal replacement therapy-free days within 28 days after randomization. The study addresses the challenge that renal replacement therapy, while life-saving, may cause complications like hypotension and organ ischemia in these patients. Participants will be randomly assigned to receive either 20-25% albumin fluid or normal saline boluses during their renal replacement therapy sessions in the intensive care unit. Each treatment involves two 100 mL boluses one at the start and one halfway through each session. The renal replacement therapies include continuous renal replacement therapy CRRT, prolonged intermittent renal replacement therapy PIRRT, or intermittent hemodialysis IHD. Treatments will continue for up to 14 days in the ICU, with dosing schedules tailored to the type of renal replacement therapy. During the study, participants will be closely monitored for organ support-free days, renal replacement therapy-free days, and other health outcomes through 28 days, with extended follow-up for mortality and kidney function up to 365 days. Researchers will collect data on fluid balance, hypotension episodes during therapy, organ function scores, healthcare costs, and quality of life measures. The trial involves multiple intensive care units and includes comprehensive assessments to evaluate the impact and safety of albumin use in this critical condition.

Age: 18Years +All GendersPhase 4
16 locations
E

Actively Recruiting

Researchers are evaluating the combination of cefazolin with ertapenem for treating methicillin-susceptible Staphylococcus aureus MSSA bacteremia, a serious bloodstream infection. This phase 2 randomized controlled trial explores whether adding ertapenem to cefazolin can improve clinical outcomes compared to cefazolin alone. MSSA bacteremia causes significant mortality, and current treatments have room for improvement, prompting this study as a sub-study of the SNAP trial. Participants will receive either ertapenem intravenously 1g daily infused over 2 hours for 5 days alongside cefazolin or a saline placebo infusion alongside cefazolin. The ertapenem targets a different bacterial protein than cefazolin, potentially enhancing treatment effectiveness. The study involves randomized assignment to one of two groups ertapenem plus cefazolin or placebo plus cefazolin. During the trial, participants will be assessed for clinical success by Day 5, and monitored up to 90 days for outcomes including blood culture clearance, clinical improvement, length of hospital stay, mortality, infections like C. difficile, and kidney injury. Safety monitoring includes tracking seizures and new bacterial colonization. Follow-up visits and evaluations will help researchers measure the impact of the combination therapy over time.

Age: 18Years - 100YearsAll GendersPhase 2
8 locations
C

Actively Recruiting

Atrial Fibrillation AF affects many individuals and raises the risk of stroke, which can severely impact daily functions such as speaking, walking, and self-care, and can be fatal. Blood clots forming in the heart due to AF can travel to the brain and cause strokes. Blood thinners, or anticoagulants, help reduce this risk by preventing clot formation. While warfarin has been widely used, newer direct oral anticoagulants DOACs like rivaroxaban and apixaban offer alternatives without the need for regular blood tests or dietary restrictions. However, there has been no direct comparison between these two newer drugs to assess their relative safety. This research compares the safety of apixaban taken twice daily and rivaroxaban taken once daily over 12 months in patients with non-valvular atrial fibrillation. Doses may be adjusted based on age, weight, kidney function, or creatinine clearance. Both groups receive treatment orally, with regular monitoring of kidney function at the start and annually. The trial aims to measure bleeding events and other outcomes during the treatment period. Participants will be followed for one year, with researchers monitoring bleeding complications, stroke or transient ischemic attack events, medication adherence, mortality, and cost-effectiveness. These assessments include clinical evaluations and tracking of any significant bleeding episodes. This trial will help inform treatment choices by comparing the safety profiles of these two anticoagulants for stroke prevention in AF.

Age: 18Years +All GendersPhase 4
8 locations
S

Actively Recruiting

This research is focused on individuals who have experienced a stroke and suffer from lasting muscle weakness in their affected upper limb, which greatly reduces their daily functioning and independence. The study aims to evaluate whether combining a personalized upper limb strength training program with a novel brain stimulation technique called cranial nerve non-invasive neuromodulation CN-NINM can improve arm motor function and promote brain plasticity in people at the chronic stage of stroke recovery. Participants will take part in a 4-week upper limb strength training program conducted three times per week, lasting 60 minutes each session. During the first 20 minutes of each session, participants will receive either real or sham CN-NINM via a device placed on the tongue that stimulates cranial nerves linked to motor control. The strength training intensity will be tailored according to each participants baseline motor evoked potential MEP amplitude, with training loads adjusted weekly to maximize recovery potential. Throughout the study, participants will undergo clinical and neurophysiological assessments before and after the intervention, including tests of upper limb motor function and measurement of brain excitability using transcranial magnetic stimulation. Researchers will monitor changes in motor ability, functional performance, range of motion, and neuroplasticity indicators to determine the effects of CN-NINM combined with tailored training. The total involvement includes a 4-week training period with detailed evaluations at baseline and post-training to measure progress and brain changes.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are evaluating DIAG723, a novel bispecific monoclonal antibody targeting ALK-1 and BMPRII, in adult patients with hereditary hemorrhagic telangiectasia HHT. This Phase 12, randomized, double-blind, placebo-controlled study aims to assess the safety, tolerability, pharmacokinetics, and early clinical effects of DIAG723. The trial includes patients with HHT alone and those with HHT plus pulmonary arterial hypertension, addressing important treatment needs in these populations. The study is divided into three parts. Part A tests single ascending subcutaneous doses of DIAG723 in sequential patient groups to evaluate safety and pharmacokinetics. Part B involves multiple doses over approximately 13 weeks in patients with HHT, and Part C also gives multiple doses over 13 weeks but in patients with both HHT and pulmonary arterial hypertension. Participants are randomly assigned to receive DIAG723 or a placebo in all parts, with dosing and regimens informed by earlier study results. Participants receive subcutaneous injections during inpatient and outpatient visits depending on the study part. Researchers monitor safety through adverse event tracking, laboratory tests, vital signs, and electrocardiograms. Pharmacokinetic blood samples and clinical assessments are performed at scheduled visits. The study measures treatment-emergent adverse events, dose-limiting toxicities, and changes in blood and clinical parameters to understand DIAG723s effects. The overall participation duration varies by study part but includes follow-up extending up to 28 days after the last dose.

Age: 18Years +All GendersPhase 1Phase 2
11 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations

1-10 of 30

1